There are currently 1277 clinical trials in Cleveland, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Cleveland Clinic, Cleveland Clinic Foundation, Case Western Reserve University and University Hospitals Cleveland Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Breast Cancer
Register for Updates
Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)
NCT04084080
Recruiting
The SCD-CARRE trial is a Phase 3, prospective, randomized, multicenter, controlled, parallel two-arm study aimed to determine if automated exchange blood transfusion and standard of care administered to high mortality risk adult SCD patients reduces the total number of episodes of clinical worsening of SCD requiring acute health care encounters (non-elective infusion center/ER/hospital visits) or resulting in death over 12 months as compared with standard of care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Sickle Cell Disease
Register for Updates
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS
NCT05267821
Recruiting
The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in children with sepsis-induced multiple organ dysfunction syndrome (MODS).
Gender:
ALL
Ages:
Between 1 day and 17 years
Trial Updated:
12/13/2024
Locations: Rainbow Babies and Children's Hospital, Cleveland, Ohio
Conditions: Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
Register for Updates
International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry
NCT04496687
Recruiting
The aim of "iSCAD," the International Spontaneous Coronary Artery Dissection (SCAD) Registry, is to serve as an internationally collaborative, multicenter registry coordinated by an experienced and centralized coordinating center in an effort to increase the pace of participant recruitment, and thereby increase statistical power of studies related to SCAD. The ultimate goal of iSCAD Registry is to facilitate the development of best practices and clinical guidelines for preventing SCAD or its re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: University Hospitals--Case Western, Cleveland, Ohio
Conditions: Spontaneous Coronary Artery Dissection
Register for Updates
A Study of Auxora in Patients with AKI and Injurious Lung "Crosstalk"
NCT06374797
Recruiting
Approximately 150 patients with acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF) will be randomized at up to 40 sites. Patients will be randomly assigned to either Auxora or matching placebo. Study drug infusions will occur every 24 hours for five consecutive days for a total of five infusions.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Acute Kidney Injury
Register for Updates
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
NCT05678673
Recruiting
This is a multicenter, randomized (2:1), open-label, controlled Phase 3 trial of XL092 in combination with nivolumab versus sunitinib in subjects with unresectable, locally advanced or metastatic nccRCC who have not received prior systemic anticancer therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: Exelixis Clinical Site #42, Cleveland, Ohio
Conditions: Non-Clear Cell Renal Cell Carcinoma
Register for Updates
A SkeleTal Muscle Recovery Intervention with Dietary Protein in Heart Failure
NCT05627440
Recruiting
Severe skeletal wasting and catabolic weight loss are highly common among patients with heart failure with reduced ejection fraction (HFrEF). This prospective randomized controlled trial will compare changes in the muscle mass in the arms and the legs (appendicular lean mass) in patients with HFrEF randomized between 3 groups of no, low- or high-dose protein supplementation. The dietary protein supplementation will be Ensure(R) products manufactured by Abbott Nutrition. The Investigators hypothe... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
12/12/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Heart Failure, Muscle Atrophy
Register for Updates
Feasibility of Triggered Sacral Neuromodulation for Neurogenic Bladder
NCT05141487
Recruiting
Incontinence associates with military service and post-traumatic stress disorder in both male and female Veterans. Neurogenic detrusor overactivity (NDO) is caused by spinal cord injury or disorder, or peripheral neurodegenerative conditions, and causes urine leakage at low volumes. NDO is disproportionately experienced by Veterans and treatment effectiveness varies greatly between individuals. This project will demonstrate the feasibility of a new type of nerve stimulation-triggered sacral neur... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio
Conditions: Urinary Incontinence, Urinary Bladder, Neurogenic
Register for Updates
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
NCT05832229
Recruiting
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/12/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C
Register for Updates
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
NCT05805709
Recruiting
The COPE-AKI study is a randomized, pragmatic, parallel-arm trial comparing a multimodal intervention to usual care on hospital-free days through 90 days of study follow up. The primary study hypothesis is that patients randomized to the intervention will have increased odds of more hospital-free days through 90 days (primary clinical) compared to those randomized to usual care. Key secondary hypotheses will investigate the impact of the intervention on rates of major adverse kidney events, rate... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: MetroHealth, Cleveland, Ohio +1 locations
Conditions: Acute Kidney Injury
Register for Updates
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
NCT06095505
Recruiting
PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1 immunotherapy agent. Up to one additional systemic anti-cancer therapy for SCLC is allowed, for a total of up to two prior lines of therapy. This study is intended to identify the biomarker-defined subgroup(s) that may benefit most from alisertib treatment and to ev... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: University Hospital - Cleveland Medical Center, Cleveland, Ohio +1 locations
Conditions: Small Cell Lung Cancer
Register for Updates
Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast
NCT06129747
Recruiting
The standard treatment for participants whose cancer has returned after breast conserving surgery is radiation given twice daily (separated by at least 6 hours) for a total of 30 treatments. The purpose of this study is to find out if giving radiation once a day for 15 treatments after repeat breast conserving surgery works as well as giving it the standard way.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
12/11/2024
Locations: University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio +1 locations
Conditions: Breast Cancer, Tumor, Breast
Register for Updates